Physician profile
Alok Singh
NPI 1427094168
$3,727.86
in general payments reported to CMS, 2019-2025
29 companies · $733 in 2025
The $733 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $219 · 2021: $316 · 2022: $487 · 2023: $756 · 2024: $686 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,174.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $472.09 | 2019-2025 | Sapien 3 Ultra Resilia |
| Abiomed | $380.54 | 2019-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $357.28 | 2019-2025 | Lifevest |
| Amgen INC. | $276.24 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $259.05 | 2019-2025 | |
| Abbott Laboratories | $240.30 | 2019-2024 | Cardiomems |
| Astrazeneca Pharmaceuticals LP | $195.31 | 2019-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $186.60 | 2022-2025 | Eliquis, Camzyos |
| Pfizer INC. | $167.81 | 2023-2025 | |
| Impulse Dynamics (USA) INC. | $134.81 | 2024 | Optimizer |
| Procyrion, INC. | $118.35 | 2024 | |
| Kestra Medical Technology Services, INC. | $116.43 | 2022-2023 | Assure Wcd |
| Biosense Webster, INC. | $102.73 | 2019 | |
| Cardiovascular Systems INC. | $102.60 | 2019-2021 | |
| Medtronic, INC. | $82.47 | 2023-2025 | Micra, Linq II, Attain Command + Surevalve |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $81.12 | 2022-2024 | |
| Novo Nordisk INC | $79.83 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boston Scientific Corporation | $65.54 | 2019-2025 | Watchman Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.43 | 2023-2025 | Jardiance |
| Angiodynamics, INC. | $55.68 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $30.71 | 2023 | Arcalyst |
| Penumbra, INC. | $28.16 | 2023-2024 | Ruby Coil, Indigo System |
| Shockwave Medical, INC | $24.26 | 2025 | |
| Cvrx, INC. | $23.01 | 2024-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $20.18 | 2023 | Verquvo |
| Cardiva Medical, INC. | $18.24 | 2025 | Optowire |
| Scpharmaceuticals INC. | $17.88 | 2024 | |
| Philips North America LLC | $17.62 | 2020 | |
| Medtronic Vascular, INC. | $14.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alok Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.